Drug−Protein Adducts: An Industry Perspective on Minimizing the

Chem. Res. Toxicol. 2005, 18, 1777

Additions and Corrections Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development [Volume 17, Number 1, January 2004, pp 3-16] DAVID C. EVANS,* ALAN P. WATT, DEBORAH A. NICOLL-GRIFFITH, AND THOMAS A. BAILLIE The authors of the above publication represented a management team charged with setting policy on how to deal with the issues of metabolic activation and covalent binding in drug discovery. In addition, a methods team (S. Day, A. Mao, R. White, T. Schulz-Utermoehl, R. Miller, and M. Beconi, Merck Research Laboratories) was charged with standardizing experimental methodology. The authors wish to clarify that the standardization of covalent binding methods presented in Section 3 (page 7) and the data presented in Tables 3 and 4 (pages 7 and 8, respectively) resulted from studies conducted by the methods team. The full details of the methodology and standardization effort have recently been published by this team (1).

References (1) Day, S. H., Mao, A., White, R., Schulz-Utermoehl, T., Miller, R., and Beconi, M. G. (2005) A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J. Pharmacol. Toxicol. Methods 52, 278-285.

TX050273D 10.1021/tx050273d Published on Web 10/08/2005

1777